Agenus Inc. (NASDAQ:AGEN) Short Interest Update

Agenus Inc. (NASDAQ:AGEN) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 2,620,000 shares, a decrease of 6.4% from the October 31st total of 2,800,000 shares. Currently, 11.8% of the company’s shares are short sold. Based on an average trading volume of 452,300 shares, the days-to-cover ratio is currently 5.8 days.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Point72 DIFC Ltd bought a new stake in shares of Agenus in the 2nd quarter valued at approximately $51,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Agenus in the second quarter worth approximately $106,000. HighTower Advisors LLC increased its stake in shares of Agenus by 46.1% during the 3rd quarter. HighTower Advisors LLC now owns 23,851 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 7,530 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after purchasing an additional 9,422 shares in the last quarter. Finally, State Street Corp lifted its stake in shares of Agenus by 2.1% in the 3rd quarter. State Street Corp now owns 467,771 shares of the biotechnology company’s stock valued at $2,563,000 after purchasing an additional 9,731 shares during the last quarter. 61.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. StockNews.com cut shares of Agenus from a “hold” rating to a “sell” rating in a research report on Monday, August 12th. B. Riley dropped their price target on Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Finally, HC Wainwright reissued a “neutral” rating and issued a $7.00 price objective on shares of Agenus in a research note on Friday. One analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $10.00.

Agenus Trading Down 2.0 %

NASDAQ AGEN opened at $3.42 on Monday. Agenus has a 1-year low of $2.50 and a 1-year high of $19.69. The firm’s fifty day simple moving average is $4.15 and its 200-day simple moving average is $8.06. The company has a market capitalization of $80.23 million, a PE ratio of -0.30 and a beta of 1.39.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.